Pfizer reports record revenue, expects Covid-19 vaccines to be commercialized later this year

Politico January 31, 2023
By Katherine Ellen Foley

Company executives said they estimated 2023 would be a transition year as the company pivots to a commercial market instead of a government market.

In 2023, Pfizer expects to bring in only $13.5 billion in revenue for the vaccine, Comirnaty, and $8 billion for Paxlovid. | Asanka Ratnayake/Getty Images

Pharmaceutical giant Pfizer expects billions less in revenue this year as the U.S. government stops buying its Covid-19 vaccine and treatments and fewer people seek shots to combat the disease.

The anticipated revenue decline underscores how federal subsidies have bolstered the drug industry during the pandemic.

Today's Sponsors

Today's Sponsor